Please confirm you are human (Sign Up for free to never see this)
← Back to Search
GSK-3 Modulates Cellular Responses To A Broad Spectrum Of Kinase Inhibitors
C. Thorne, Chonlarat Wichaidit, Adam D. Coster, Bruce A. Posner, L. Wu, S. Altschuler
Published 2015 · Biology, Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
A fundamental challenge in treating disease is identifying molecular states that affect cellular responses to drugs. Here, we focus on GSK-3, a key regulator for many of the hallmark behaviors of cancer cells. We alter GSK-3 activity in colon epithelial cells to test its role in modulating drug response. We find that GSK-3 activity broadly affects the cellular sensitivities to a panel of oncology drugs and kinase inhibitors. Specifically, inhibition of GSK-3 activity can strongly desensitize or sensitize cells to kinase inhibitors (e.g. mTOR or PLK1 inhibitors, respectively). Additionally, colorectal cancer cell lines, in which GSK-3 function is commonly suppressed, are resistant to mTOR inhibitors and yet highly sensitive to PLK1 inhibitors and this is further exacerbated by additional GSK-3 inhibition. Finally, by conducting a kinome-wide RNAi screen, we find that GSK-3 modulates the cell proliferative phenotype of a significant fraction (~35%) of the kinome, which includes ~50% of current, clinically relevant kinase-targeted drugs. Our results highlight an under-appreciated interplay of GSK-3 with therapeutically important kinases and suggest strategies for identifying disease-specific molecular profiles that can guide optimal selection of drug treatment.
This paper references
Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Clinical cancer research: an official journal of the American Association for Cancer Research
D Rudolph (2009)
Phosphoserine as a recognition determinant for glycogen synthase kinase-3: phosphorylation of a synthetic peptide based on the G-component of protein phosphatase-1.
C. Fiol (1988)
Role of Glycogen Synthase Kinase-3 in the Phosphatidylinositol 3-Kinase/Akt Cell Survival Pathway*
M. Pap (1998)
Expression, localization, and activity of glycogen synthase kinase 3β during mouse skin tumorigenesis
Hugo Leis (2002)
A simple image correction method for high-throughput microscopy
Adam D. Coster (2014)
An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1*
C. Thoreen (2009)
Polo on the Rise-from Mitotic Entry to Cytokinesis with Plk1.
M. Petronczki (2008)
Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies
D. Olmos (2011)
A complex interplay between Akt, TSC2 and the two mTOR complexes.
Jingxiang Huang (2009)
GSK-3 inhibitors induce chromosome instability
A. Tighe (2007)
Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
Morris E. Feldman (2009)
Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive
E. Jacinto (2004)
Comprehensive Molecular Characterization of Human Colon and Rectal Cancer
D. M. Muzny (2012)
Phosphorylated GSK3beta-ser9 and EGFR are good prognostic factors for lung carcinomas.
H. Zheng (2007)
GSK-3: tricks of the trade for a multi-tasking kinase
B. Doble (2003)
A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation.
S. Frame (2001)
Control of β-Catenin Phosphorylation/Degradation by a Dual-Kinase Mechanism
C. Liu (2002)
Small-molecule inhibition of Wnt signaling through activation of casein kinase 1α.
C. Thorne (2010)
Functional redundancy of GSK-3α and GSK-3β in wnt/β-catenin signaling shown by using an allelic series of embryonic stem cell lines
B. Doble (2007)
Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-Kinase/Akt cell survival pathway. The Journal of biological chemistry
M Pap (1998)
Functional redundancy of GSK-3alpha and GSK-3beta in Wnt/beta-catenin signaling shown by using an allelic series of embryonic stem cell lines.
B. Doble (2007)
GSK3, a master switch regulating cell-fate specification and tumorigenesis.
L. Kim (2000)
GSK-3 beta targets Cdc25A for ubiquitin-mediated proteolysis, and GSK-3 beta inactivation correlates with Cdc25A overproduction in human cancers.
T. Kang (2008)
mTOR and cancer: insights into a complex relationship
D. Sabatini (2006)
Dual regulation of Snail by GSK-3β-mediated phosphorylation in control of epithelial–mesenchymal transition
B. Zhou (2004)
The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3.
C. Yost (1996)
Regulation of Wnt signaling during adipogenesis
CN Bennett (2002)
Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism.
Chunming Liu (2002)
Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton
D. Sarbassov (2004)
Direct small-molecule kinase activation: Novel approaches for a new era of drug discovery.
G. L. Simpson (2009)
A GSK3‐binding peptide from FRAT1 selectively inhibits the GSK3‐catalysed phosphorylation of Axin and β‐catenin
G. M. Thomas (1999)
Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology.
P. Schöffski (2009)
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt.
Kathryn E. O'Reilly (2006)
DrugBank 3.0: a comprehensive resource for ‘Omics’ research on drugs
Craig Knox (2011)
Kinase-inactive glycogen synthase kinase 3beta promotes Wnt signaling and mammary tumorigenesis.
M. Farago (2005)
Immortalized epithelial cells derived from human colon biopsies express stem cell markers and differentiate in vitro.
Andres I. Roig (2010)
S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition of Akt.
H. Zhang (2006)
A Neo-Substrate that Amplifies Catalytic Activity of Parkinson’s-Disease-Related Kinase PINK1
Nicholas T Hertz (2013)
What Are the bona fide GSK3 Substrates?
C. Sutherland (2011)
Rapamycin inhibits mTORC1, but not completely
C. Thoreen (2009)
ER Stress Inhibits mTORC2 and Akt Signaling Through GSK-3β–Mediated Phosphorylation of Rictor
Chien-Hung Chen (2011)
mTOR and cancer: many loops in one pathway.
A. Efeyan (2010)
Small-molecule inhibition of Wnt signaling through activation of casein kinase 1alpha
CA Thorne (2010)
BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity
D. Rudolph (2009)
Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. The oncologist
P Schoffski (2009)
This paper is referenced by
Progress Towards a Public Chemogenomic Set for Protein Kinases and a Call for Contributions
D. Drewry (2017)
Molecular Pathways: Revisiting Glycogen Synthase Kinase-3β as a Target for the Treatment of Cancer
A. Walz (2017)
Chromomycin A2 potently inhibits glucose-stimulated insulin secretion from pancreatic β cells
Michael A. Kalwat (2018)
Highly multiplexed imaging of single cells using a high-throughput cyclic immunofluorescence method
Jia-Ren Lin (2015)
Progress towards a public chemogenomic set for protein kinases and a call for contributions
D. Drewry (2017)
Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells
M. Ramirez (2016)
Discovery of a Highly Selective Glycogen Synthase Kinase-3 Inhibitor (PF-04802367) That Modulates Tau Phosphorylation in the Brain: Translation for PET Neuroimaging.
S. Liang (2016)
Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma.
X. Wu (2019)
Combination Treatment with the GSK-3 Inhibitor 9-ING-41 and CCNU Cures Orthotopic Chemoresistant Glioblastoma in Patient-Derived Xenograft Models12
A. Ugolkov (2017)
Are Wnt/β-Catenin and PI3K/AKT/mTORC1 Distinct Pathways in Colorectal Cancer?
A. Prossomariti (2020)
Chemical compound cinobufotalin potently induces FOXO1-stimulated cisplatin sensitivity by antagonizing its binding partner MYH9
Y. Li (2019)
Drug discovery for psychiatric disorders using high-content single-cell screening of signaling network responses ex vivo
S. Lago (2019)
Xanthatin anti-tumor cytotoxicity is mediated via glycogen synthase kinase-3β and β-catenin.
Li Tao (2016)
A novel pipeline for drug discovery in neuropsychiatric disorders using high-content single-cell screening of signalling network responses ex vivo
Lago Cooke (2016)
Role of Polo-like kinase 1 in the regulation of the action of p31comet in the disassembly of mitotic checkpoint complexes
S. Kaisari (2019)
High Throughput Chemical Screening Reveals Multiple Regulatory Proteins on FOXA1 in Breast Cancer Cell Lines
Shixiong Wang (2018)
Global Approaches to Understanding Protein Kinase Functions
Jennifer L. Gorman (2015)
GSK-3 Inhibitors and Tooth Repair: An Ethical Analysis
S. Hostiuc (2019)
TGF‐β inhibits IL‐7‐induced proliferation in memory but not naive human CD4+ T cells
T. P. Nguyen (2017)
Glycogen synthase kinase-3 beta inhibitors as novel cancer treatments and modulators of antitumor immune responses
I. Sahin (2019)
Glycogen synthase kinase-3ß supports serotonin transporter function and trafficking in a phosphorylation-dependent manner.
Ragu Varman Durairaj (2020)